New Delhi: Wockhardt shares slumped 14 percent intraday on Monday after its third plant got US Food and Drugs Administration (FDA) import alert.
The US regulator has issued import alert on Ankleshwar plant for violating good manufacturing practices.
The inspection by the FDA was conducted in November 2015, after which it issued certain observations (483s).
The import alert possibly implies that the agency is not satisfied with the company’s proposed corrective plan.
Wockhardt’s two major formulation plants in India are already subject to US import bans and most of the company’s US revenues are being serviced by its plant in the US.
Macquarie has downgraded the shares to neutral from outperform and reduced target price to Rs. 1015 versus Rs. 1350 per share.
The Ankleshwar facility receiving under import alert may lead to multiples falling under pressure in the near term, says Macquarie.
The drug major’s Waluj and Chikalthana plants are already under USFDA import alert. (ANI)